Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development expenses	$ 6,704,164	$ 5,843,686
General and administrative expenses	3,393,463	3,578,728
Total operating expenses	10,097,627	9,422,414
Loss from operations	(10,097,627)	(9,422,414)
Interest income (expenses), net
Interest income	668,895	729,341
Interest expense	(1,174,745)	(966,845)
Interest income (expense), net	(505,850)	(237,504)
Net loss	(10,603,477)	(9,659,918)
Comprehensive loss	$ (10,603,477)	$ (9,659,918)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.3)	$ (0.32)
Net loss per share, diluted (in dollars per share)	$ (0.3)	$ (0.32)
Weighted average common shares outstanding, basic (in shares)	34,815,870	30,428,053
Weighted average common shares outstanding, diluted (in shares)	34,815,870	30,428,053